POLE Mutation is an inclusion criterion in 20 clinical trials for malignant solid tumor, of which 18 are open and 2 are closed. Of the trials that contain POLE Mutation and malignant solid tumor as inclusion criteria, 8 are phase 1 (8 open), 4 are phase 1/phase 2 (2 open), and 8 are phase 2 (8 open) [5].

POLE Mutation is an inclusion criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain POLE Mutation and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [5].

POLE Mutation is an inclusion criterion in 7 clinical trials for endometrial carcinoma, of which 7 are open and 0 are closed. Of the trials that contain POLE Mutation and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].

POLE Mutation is an inclusion criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain POLE Mutation and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].

POLE Mutation is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 4 are open and 1 is closed. Of the trials that contain POLE Mutation and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 5 clinical trials for ovarian carcinoma, of which 4 are open and 1 is closed. Of the trials that contain POLE Mutation and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain POLE Mutation and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain POLE Mutation and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain POLE Mutation and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain POLE Mutation and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 3 clinical trials for primary peritoneal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain POLE Mutation and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE Mutation and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

POLE Mutation is an inclusion criterion in 2 clinical trials for central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain POLE Mutation and central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 2 clinical trials for colorectal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE Mutation and colorectal adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

POLE Mutation is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE Mutation and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

POLE Mutation is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE Mutation and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE Mutation and head and neck carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

POLE Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain POLE Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain POLE Mutation and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

POLE Mutation is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain POLE Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

POLE Mutation is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 1 is open and 1 is closed. Of the trials that contain POLE Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 2 clinical trials for urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE Mutation and urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for adnexal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and adnexal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains POLE Mutation and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for basal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and basal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for endometrial adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and endometrial adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for endometrial serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and endometrial serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for endometrial undifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and endometrial undifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for fallopian tube clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and fallopian tube clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for fallopian tube endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for high grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for non-clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and non-clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains POLE Mutation and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for primary peritoneal clear cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and primary peritoneal clear cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for primary peritoneal endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and primary peritoneal endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of the penis, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and squamous cell carcinoma of the penis as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains POLE Mutation and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains POLE Mutation and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

POLE Mutation is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains POLE Mutation and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].